Wide Ranks

ME

23andMe Holding Co.

3.14

Top Statistics
Market Cap 82 M Forward PE -0.0616 Revenue Growth -33.60 %
Current Ratio 1.52 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.0990 Enterprise / Revenue 0.1170 Price To Sales Trailing12 Months 0.4117
Profitability
Profit Margins 0.00 % Operating Margins -178.05 %
Balance Sheet
Total Cash 169 M Total Cash Per Share 6.72 Total Debt 74 M
Total Debt To Equity 51.68 Current Ratio 1.52 Book Value Per Share 7.69
All Measures
Short Ratio 452.00 % Message Board Id finmb_34511998 Shares Short Prior Month 1 M
Return On Equity -1.54 City South San Francisco Uuid 9ee9d85a-86f0-318c-80ba-2385bb314fd7
Previous Close 3.16 First Trade Date Epoch Utc 1 B Book Value 7.69
Beta 1.26 Total Debt 74 M Volume 339361
Price To Book 0.4082 Last Split Date 1 B Fifty Two Week Low 2.65
Total Cash Per Share 6.72 Total Revenue 199 M Shares Short Previous Month Date 1 B
Audit Risk 4 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -178.05 % Net Income To Common -631480000 Short Percent Of Float 0.0615
Implied Shares Outstanding 26 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 691560 Average Volume10days 691560 Total Cash 169 M
Next Fiscal Year End 1 B Revenue Per Share 8.22 Held Percent Insiders 0.0365
Ebitda Margins -118.04 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 10 Regular Market Previous Close 3.16
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.09
Open 3.17 Free Cashflow -1551000 State CA
Dividend Yield 0.00 % Return On Assets -0.2577 Time Zone Short Name EST
Board Risk 10 Trailing Eps -122.52 Day Low 3.11
Address1 349 Oyster Point Boulevard Shares Outstanding 19 M Compensation Risk 8
Price Hint 4 Target High Price 0.0000 Website https://www.23andme.com
52 Week Change -0.8177 Average Volume 297640 Forward Eps -51.00
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 129.40 %
Last Split Factor 1:20 Regular Market Day High 3.39 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 51.68 Fifty Two Week High 20.40
Day High 3.39 Shares Short 1 M Regular Market Open 3.17
Industry Key diagnostics-research Earnings Growth 0.00 % Enterprise To Revenue 0.1170
Revenue Growth -33.60 % Shares Percent Shares Out 0.0398 Operating Cashflow -138234000
Currency USD Time Zone Full Name America/New_York Market Cap 82 M
Is_nasdaq_100 False Zip 94080 Quote Type EQUITY
Industry Diagnostics & Research Long Name 23andMe Holding Co. Overall Risk 10
Regular Market Day Low 3.11 Held Percent Institutions 0.3333 Current Price 3.14
Enterprise To Ebitda -0.0990 Financial Currency USD Current Ratio 1.52
Gross Margins 44.79 % Industry Disp Diagnostics & Research Country United States
Float Shares 16 M Two Hundred Day Average 8.13 Governance Epoch Date 1 B
Enterprise Value 23 M Price To Sales Trailing12 Months 0.4117 Forward PE -0.0616
Regular Market Volume 339361 Ebitda -235118000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
23andMe Holding Co.

operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally.

The company operates in two segments, Consumer and Research Services, and Therapeutics.

The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.

This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services.

The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates.

This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway.

23andMe Holding Co.

was founded in 2006 and is headquartered in South San Francisco, California.